加科思-B(01167)在2024年第66届美国血液学会年会上展示了BET抑制剂JAB-8263 治疗骨髓纤维化(MF)临床一期的初步数据

智通财经
09 Dec 2024

智通财经APP讯,加科思-B(01167)发布公告,公司在加利福尼亚州圣地牙哥举行的2024年第66届美国血液学会(ASH)年会上展示了BET抑制剂JAB-8263 治疗骨髓纤维化(MF)临床一期的初步数据。

资料显示,JAB-8263具有良好的耐受性,二期推荐剂量为0.3毫克(每日给药)。 JAB-8263单药治疗骨髓纤维化适应症的初步疗效资料是令人鼓舞的。大多数患者出现脾脏缩小(spleen volume reduction, SVR)以及总症状评分(total symptom score,TSS)的降低。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10